February 14, 2014. As members of the Patient, Consumer, and Public Health Coalition, we strongly oppose the Preventing Regulatory Overrreach To Enhance Care Technology (PROTECT) Act of 2014.
Read More »On Health Policy
NCHR Comments on FDA’s Proposed Rule Regarding Labeling Changes for Approved Drugs and Biological Products
February 10, 2014. As members of the Patient, Consumer, and Public Health Coalition, we are pleased to have the opportunity to strongly support the Food and Drug Administration’s (FDA) proposed rule entitled, Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products (78 Fed. Reg. 67985).
Read More »Letter to Congresswoman Rosa DeLauro in Support of Strengthening FDA Safeguards
February 6, 2014. We are writing to thank Representative Rosa DeLauro for her dedication to patients and consumers and work to strengthen safeguards for all medical products sold in the United States.
Read More »Patient, Consumer, and Public Health Coalition Comments on FDA Draft Guidance on Pharmacy Compounding of Human Drug Products
February 6, 2014. As members of the Patient, Consumer, and Public Health Coalition, we conditionally support the draft guidance “Pharmacy Compounding of Human Drug Products Under Section 503A of the Federal Food, Drug, and Cosmetic Act” (FD&C) because it clarifies FDA enforcement actions that can be taken against individuals or firms that illegally make drugs under the banner of traditional compounding.
Read More »NCHR Testimony on NIOSH Draft Intelligence on Carcinogen Classification and Target Risk Level Policy for Chemical Hazards in the Workplace
December 16, 2013. When notorious and decades-known carcinogens such as asbestos and radon are still present at unsafe or unknown levels in American workplaces, how can the public have confidence that our regulations can handle new and complex occupational hazards arising every day?
Read More »